KLK3 and posterior cortical atrophy: In recent years, a number of novel biomarkers that appear to outperform PSA have been suggested, with the potential for these to be used to better detect PCa and distinguish between individuals who will benefit from active treatment from those who will not, as well as aid in the improved outcome of surgery [38,39].